IDO1 and TDO2 are the first rate-limiting metalloenzymes that are responsible for the degradation from TRP to kynurenine, which is closely correlated to the failure of anticancer immunotherapies and tumor progression through the activation of AhR [38,43]. Here, AHR is linked to neoplasm.